{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6","value":"2"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"9","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.","dispersionType":"Full Range","groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG001","title":"Group II (auto HSCT)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 60 days","title":"Median Number of Days of Febrile Neutropenia During the Auto HSCT Inpatient Stay","type":"SECONDARY","unitOfMeasure":"days of inpatient febrile neutropenia"}